Kenvue Inc. (NYSE:KVUE) Shares Bought by TrueMark Investments LLC

TrueMark Investments LLC raised its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 9.3% in the 4th quarter, HoldingsChannel reports. The fund owned 190,595 shares of the company’s stock after buying an additional 16,161 shares during the quarter. TrueMark Investments LLC’s holdings in Kenvue were worth $4,069,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Grove Bank & Trust boosted its holdings in Kenvue by 438.4% in the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after purchasing an additional 947 shares in the last quarter. Geneos Wealth Management Inc. acquired a new position in shares of Kenvue in the 4th quarter valued at $29,000. SRS Capital Advisors Inc. grew its position in shares of Kenvue by 67.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after buying an additional 571 shares during the last quarter. Fortitude Family Office LLC raised its stake in Kenvue by 106.6% during the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after acquiring an additional 777 shares in the last quarter. Finally, Versant Capital Management Inc lifted its position in Kenvue by 300.8% in the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock valued at $41,000 after acquiring an additional 1,441 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Stock Performance

Shares of KVUE stock opened at $23.08 on Wednesday. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The stock has a 50 day simple moving average of $22.17 and a 200-day simple moving average of $22.44. The company has a market cap of $44.11 billion, a price-to-earnings ratio of 43.55, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, equities analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were given a dividend of $0.205 per share. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.55%. Kenvue’s payout ratio is currently 154.72%.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Canaccord Genuity Group raised their price objective on Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday, March 5th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $24.00 price target on shares of Kenvue in a research report on Monday, February 3rd. UBS Group reduced their price objective on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research note on Friday, February 7th. Citigroup lowered their target price on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 15th. Finally, Evercore ISI assumed coverage on shares of Kenvue in a research report on Monday. They issued an “in-line” rating and a $25.00 price target for the company. One analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $23.85.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.